RxDoctor Payments Data

Michael Angelillo, DO

Internal Medicine · Boca Raton, FLNPI 1386153807

Payments from drug & device makers

$904in general payments, 2019–2025

Across 39 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$135
  • Pfizer$125
  • AbbVie$106
  • Novartis$105
  • GSK$102
  • Novo Nordisk$93
  • plus $239 from 8 others

What the payments were for

  • Food & beverage$904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$904 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$374,371
Medicare patients
974
Services billed
5,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$88,036
JardianceEmpagliflozin46$53,905
XareltoRivaroxaban27$41,573
Repatha SureclickEvolocumab26$26,178
LinzessLinaclotide27$22,116
EntrestoSacubitril/Valsartan12$18,398
OzempicSemaglutide14$17,668
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,085
MounjaroTirzepatide14$14,674
MyrbetriqMirabegron19$11,002
Praluent PenAlirocumab14$10,697
Atorvastatin Calcium622$6,278
Rosuvastatin Calcium377$6,079
Levothyroxine Sodium437$5,346
SynthroidLevothyroxine Sodium55$4,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$125$89,46592 claims
Johnson & JohnsonXarelto$135$41,57327 claims
AbbVieLinzess, Synthroid$106$26,69282 claims
NovartisEntresto$105$18,39812 claims
Novo NordiskOzempic$93$17,66814 claims
GSKTrelegy Ellipta$102$15,08517 claims
Astellas Pharma US IncMyrbetriq$50$11,00219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →